Is Moderna a Good Stock to Buy Right Now?

Moderna (NASDAQ: MRNA) recently announced an impressive efficacy of 94.5% from a late-stage study of coronavirus vaccine candidate mRNA-1273. The biotech stock jumped on the good news, but is it still a good pick to buy? That's the question that Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights address in this Motley Fool Live video recorded on Nov. 16, 2020.

Source Fool.com